Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2024-11-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by a regulatory authority (Zhejiang Provincial Drug Administration). It includes details about the certificates, product names, registration numbers, validity periods, and intended uses. The document also discusses the potential impact on company performance and includes a risk warning. The document is short (1044 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is not a report but an announcement of a regulatory approval event. There is no indication of it being a financial report, management change, voting result, or other specific filing types. Therefore, it best fits the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-22 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by the Zhejiang Provincial Drug Administration. It includes details about the certificates, product names, registration numbers, validity periods, and intended uses. The document also discusses the potential impact on company performance and includes a risk warning. There is no financial data, no mention of financial results, no management discussion, no voting results, no share transactions, and no regulatory certifications. The document is a formal announcement of a regulatory approval related to product registration, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information about the registration certificates. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-08 Chinese
2024年第三季度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (504 characters) about the disclosure of the company's 2024 third quarter report. It states that the report was approved by the board and will be published on a regulatory website. The text does not contain the actual financial data or detailed report content but serves as a notice to investors to check the full report elsewhere. According to the 'MENU VS MEAL' rule, this is a Report Publication Announcement (RPA), not the report itself.
2024-10-25 Chinese
关于收到《传票》暨诉讼事项的进展公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the receipt of a court summons (传票) and updates on ongoing litigation involving the company and its subsidiary. It details the background of the lawsuit, court proceedings, and the current status of the case, including the first instance judgment and the appeal process. There is no financial data, earnings information, or report publication mentioned. The content focuses on legal proceedings and litigation updates, which fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2024-10-25 Chinese
中天国富证券有限公司关于美康生物科技股份有限公司部分募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a sponsoring securities company regarding the delay in certain investment projects funded by proceeds from a specific stock issuance by the company 美康生物科技股份有限公司. It includes detailed financial figures about the raised funds, project progress, reasons for delay, re-evaluation of project feasibility, and approvals from the board and supervisory committee. The document references regulatory compliance and internal approvals related to the use of raised funds. It is not an announcement of a report but a substantive report itself containing financial data and management discussion about the use of raised capital and project progress. This fits the category of Capital/Financing Update (CAP), as it deals with updates on the use and management of raised capital and investment projects funded by such capital.
2024-10-25 Chinese
关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 美康生物科技股份有限公司 regarding the delay in some of its fundraising investment projects. It details the original and adjusted timelines for the projects, the reasons for the delay, the impact on the company, and the approvals from the board, supervisory committee, and the sponsoring institution. The document includes specific financial figures related to the fundraising and usage of funds but does not contain comprehensive financial statements or detailed financial performance data. It is primarily an update on the use and progress of capital raised through a specific share issuance and the adjustment of project timelines. This fits the category of a Capital/Financing Update (CAP), as it relates to the company's fundraising activities and capital usage updates rather than a full financial report or other types of filings.
2024-10-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.